This is a single arm, open-label, phase II trial investigating the combination of ivonescimab with standard FOLFOX chemotherapy in 1L therapy for HER2- GEA.

Start Date12 Dec 2025

Sponsor / Collaborator

The Massachusetts General Hospital

[+1]

NCT07057791

/ Not yet recruitingPhase 2IIT

Phase II Dose Optimization Study of Platinum/Etoposide Plus Ivonescimab (CEI) as First-Line Treatment of Extensive-Stage Small Cell Lung Cancer

Eligible untreated participants with Extensive Stage Small Cell Lung Cancer (ES-SCLC) who are ? 18 years of age will be randomized to receive ivonescimab 10 milligrams per kilogram (mg/kg) or ivonescimab 20 mg/kg in combination with carboplatin and etoposide.
Ivonescimab is a type of drug called a bispecific antibody. Antibodies are proteins that specifically recognize and bind to other types of proteins called antigens. Antibodies and antigens can work together to help the immune system fight cancer cells. Bispecific antibody, meaning it targets two different molecules at the same time.
Ivonescimab is a new drug that may help the immune system attack cancer cells and may also block certain pathways that cancer uses to grow and spread. This dual action of ivonescimab aims to help the immune system to fight the cancer and also disrupt tumor growth by blocking blood vessel formation that tumors use to grow.
Participants will receive induction with 4 cycles of ivonescimab (dose determined by randomization) with standard of care carboplatin and etoposide followed by maintenance therapy with ivonescimab at the same dose received during induction. Treatment will continue until disease progression, unacceptable toxicity or participant withdrawal.
The purpose of this study is to determine what dose of ivonescimab works best in combination with carboplatin and etoposide chemotherapy in ES-SCLC. We will also examine the side effects, good and bad, associated with ivonescimab.

Start Date01 Dec 2025

Sponsor / Collaborator

Summit Therapeutics, Inc.

NCT06940518

/ RecruitingPhase 2IIT

Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma

To learn if ivonescimab can help to control previously treated, locally advanced or metastatic ccRCC.

Start Date02 Jul 2025

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

[+1]

100 Clinical Results associated with Ivonescimab

100 Translational Medicine associated with Ivonescimab

100 Patents (Medical) associated with Ivonescimab

Literatures (Medical) associated with Ivonescimab

31 Dec 2025·mAbs

Antibodies to watch in 2025

Review

Author: Kapoor, Vaishali ; Kaplon, Hélène ; Crescioli, Silvia ; Visweswaraiah, Jyothsna ; Reichert, Janice M. ; Wang, Lin

The commercial development of antibody therapeutics is a global enterprise involving thousands of biopharmaceutical firms and supporting service organizations. To date, their combined efforts have resulted in over 200 marketed antibody therapeutics and a pipeline of nearly 1,400 investigational product candidates that are undergoing evaluation in clinical studies as treatments for a wide variety of diseases. Here, we discuss key events in antibody therapeutics development that occurred during 2024 and forecast key events related to the late-stage clinical pipeline that may occur in 2025. In particular, we report on 21 antibody therapeutics granted a first approval in at least one country or region during 2024, including bispecific antibodies tarlatamab (IMDELLTRA®), zanidatamab (Ziihera®), zenocutuzumab (BIZENGRI®), odronextamab (Ordspono®), ivonescimab (®), and antibody-drug conjugate (ADC) sacituzumab tirumotecan (®). We also discuss 30 investigational antibody therapeutics for which marketing applications were undergoing review by at least one regulatory agency, as of our last update on December 9, 2024, including ADCs datopotamab deruxtecan, telisotuzumab vedotin, patritumab deruxtecan, trastuzumab botidotin, becotatug vedotin, and trastuzumab rezetecan. Of 178 antibody therapeutics we include in the late-stage pipeline, we summarize key data for 18 for which marketing applications may be submitted by the end of 2025, such as bi- or multispecific antibodies denecimig, sonelokimab, erfonrilimab, and anbenitamab. Key trends in the development and approval of antibody formats such as bispecifics and ADCs, as well as clinical-phase transition and global approval success rates for these antibody formats, are reported.

01 Aug 2025·Nature Reviews Clinical Oncology

The next generation of immunotherapies for lung cancers

Review

Author: Yang, Weiwei ; Zhang, Li ; Zhao, Hongyun ; Zhao, Shen

Immunotherapies, specifically immune-checkpoint inhibitors (ICIs) targeting PD-(L)1 or CTLA4, have revolutionized the treatment of lung cancer; however, many patients do not have a response to ICIs and most of those with an initial tumour response eventually have disease progression owing to acquired resistance. Over the past few years, numerous therapeutic strategies have been explored to address the problems of intrinsic and acquired resistance to ICIs. In 2024, regulatory approvals of the bispecific PD-1 × VEGF antibody ivonescimab for the treatment of non-small-cell lung cancer in China and the bispecific DLL3 × CD3 T cell engager tarlatamab for patients with small cell lung cancer in the USA provided clinical proof-of-concept for overcoming the challenge of ICI resistance using novel immunotherapeutic agents, thereby increasing enthusiasm for the exploration of next-generation immunotherapies for lung cancer. A large variety of immunotherapies with diverse targets and mechanisms of action are currently being tested in clinical trials involving patients with lung cancer. In this Review, we provide an overview of these emerging immunotherapies in clinical development for non-small-cell lung cancer and/or small cell lung cancer, including novel immune-checkpoint modulators, immune cell engagers, adoptive cell therapies and therapeutic cancer vaccines. We describe the designs of these agents and the mechanisms by which they might overcome resistance to the current generation of ICIs. We also discuss hurdles impeding the clinical translation of each immunotherapeutic modality and potential strategies to address these challenges, using representative examples of agents that have entered the later phases of clinical testing.

12 Jun 2025·Antibody therapeutics

A novel bispecific antibody CVL006 superior to AK112 for dual targeting of PD-L1 and VEGF in cancer therapy

Article

Author: Shen, Xiaokun ; Huang, Hao ; Wu, Ziai ; Cao, Liang ; Pan, Junfang ; Li, Zhongyuan ; Song, Zeng ; Chen, XiaoBing ; Wang, Chunyan ; Huang, Jinwen

Abstract:

Background:

Preclinical and clinical studies highlight the enhanced anticancer efficacy of combining anti-VEGF/VEGFR drugs with immune checkpoint inhibitors (ICIs). PD-L1/VEGF bispecific antibodies outperform monotherapy or combined PD-L1 inhibitors and anti-VEGF antibodies by simultaneously blocking the PD-1/PD-L1 immune pathway and VEGF-driven angiogenesis, providing a dual mechanism for superior antitumor activity.

Methods:

We developed CVL006, a novel bispecific antibody, by fusing an anti-PD-L1 VHH domain with a humanized IgG1 anti-VEGF monoclonal antibody. CVL006 retains antibody-dependent cellular cytotoxicity (ADCC) functionality. Preclinical evaluations included binding affinity and specificity assessments, dual-pathway blockade testing, and in vivo efficacy comparisons to atezolizumab and PD-1/VEGF bispecific antibody AK112 (ivonescimab).

Results:

CVL006 demonstrated high affinity and specificity for human PD-L1 and VEGF. It effectively inhibited VEGF/VEGFR signaling and the PD-L1/PD-1 axis, suppressing VEGF-induced angiogenesis and reactivating T cells. This reactivation led to increased cytokine secretion critical for immune response. In vivo studies revealed CVL006’s superior antitumor efficacy, achieving greater tumor growth inhibition and angiogenesis suppression than atezolizumab. CVL006 also outperformed AK112 in preclinical models, showcasing robust antitumor activity.

Conclusions:

CVL006 integrates immune checkpoint inhibition and tumor vascularization disruption, offering a comprehensive anticancer strategy. Its superior preclinical performance compared to atezolizumab and AK112 underscores its therapeutic potential, paving the way for further development and clinical translation.

227

News (Medical) associated with Ivonescimab

12 Aug 2025

·endpoints.news

Summit, the hottest PD-1xVEGF biotech, is burning cash fast — but it may not be cause for alarm

Late Monday, Summit Therapeutics issued a “going concern” warning in its quarterly earnings filing, a disclosure more common with biotechs circling the drain after major failures — not a $20 billion market cap darling that’s at the forefront of one of the sector’s hottest cancer modalities. But Summit, which has $298 million in cash and equivalents, according to an SEC filing, has been quickly burning cash to run global trials of its PD-1xVEGF antibody ivonescimab and bring it to market. That led the company’s auditors to add the warning that Miami-based Summit has less than 12 months of cash available to pay expenses. It’s rare, perhaps “unprecedented,” for that accounting lingo to show up in the quarterly disclosure of a biotech like Summit, Cantor analysts wrote in a Tuesday note to clients. But it’s also likely of little cause for concern, said the analysts, who noted that Summit has “plenty of options” to bring in more money. It’s also not the first time the company has issued the warning. “But the going concern language does highlight management’s highly unconventional approach towards capitalizing the company,” the Cantor analysts continued. “Historically, most $20B biotech companies carry billions in cash reserves.” The Cantor analysts said it can be an interpretation of “ownership” culture in Summit’s C-suite. The company hasn’t overcapitalized like many other biotechs and there “appears to be no hedging of bets or stocking up on cash for a rainy day.” Since early 2023, Summit has had the ex-China rights to Akeso-partnered ivonescimab. The drug has been approved for certain cancer indications in China. After ivonescimab topped Merck’s Keytruda in a pivotal trial in May 2024, the pharma industry went on a shopping spree to find similar assets in the space. BioNTech bought its Chinese biotech partner and then flipped that into a major partnership with Bristol Myers Squibb just months later. Merck licensed a program from China-based LaNova Medicines . Pfizer licensed a program from Chinese biotech 3SBio . Other biotechs are in the mix . And AstraZeneca has reportedly shown interest: The UK pharma giant was in talks with Summit about a potential $15 billion licensing deal, Bloomberg News reported in early July. If it needs more cash in the short term, Summit could tap into existing registered stock offerings, which would let it quickly sell more shares. It increased the amount available to sell by $360 million on Monday, but said it’s not obligated to sell . The upsized at-the-market offering “could provide the company with temporary alleviation of their cash overhang, but it does not preclude the need to partner” on ivonescimab, Leerink Partners analysts wrote in a note to clients on Tuesday. Summit’s stock price $SMMT was down 11% in Tuesday afternoon trading, possibly because the company hasn’t locked up its plans to submit the drug to the FDA for US approval. “At present time,” Summit plans to ask the FDA to approve ivonescimab based on results from a trial that read out a few months ago. But Summit is still considering when it will submit that approval request, the company reiterated in Monday’s quarterly update , echoing comments it made in May.

Drug ApprovalLicense out/in

12 Aug 2025

·www.fiercepharma.com

Summit skips routine quarterly investor call as deal rumors swirl

Industry watchers are still awaiting detailed data or readouts from three ivonescimab phase 3 trials. Summit Therapeutics, which has consistently been communicating quarterly results through investor calls in the past few years, has suddenly decided to go without one.The lack of an earnings call accompanying Summit’s second-quarter results came after Bloomberg last month reported that the company was engaged in high-stakes licensing talks for its PD-1xVEGF antibody ivonescimab.“Coincidence? We don’t think so, as we’re unsure how else to explain the radio silence,” Evercore ISI analysts wrote in a Monday note.“The silence is deafening,” the analysts continued, noting that Summit’s second-quarter press release lacks new information but serves mostly as a recount of past events without any comments from the management team.Companies may opt not to hold conference calls if they are in the process of a major, market-moving development to avoid making any statements that could impact their discussions or violate confidentiality agreements.Last month, Bloomberg reported that Summit was in discussions with AstraZeneca for a potential deal worth $15 billion. The biotech had also talked to other large pharma companies, according to Bloomberg, citing people familiar with the matter.“We continue to believe it is critical that Summit secure a partnership that will support VEGFA/PD-1 ivonescimab’s global development,” Leerink Partners analysts said in a note this week, arguing that the company lacks the means to rapidly advance the drug in combination regimens by itself. On Monday, Summit proposed to raise up to $360 million by selling new shares of its stock from time to time. As of the end of June, Summit had cash and cash equivalents worth nearly $298 million.The new money “could provide the company with temporary alleviation of their cash overhang, but it does not preclude the need to partner [ivonescimab],” the Leerink team said. The question remains as to which pharma giant has a robust enough pipeline to pair with ivonescimab and enough firepower to pull off a deal. Summit, which currently revolves solely around ivonescimab, has a market cap of above $20 billion.Pfizer recently shelled out $1.25 billion upfront—and committed up to $4.8 billion in milestones—for 3SBio’s PD-1xVEGF candidate, coded SSGJ-707. Then Bristol Myers Squibb agreed to pay BioNTech $3.5 billion upfront, with up to $7.6 billion in potential milestones, to co-develop and co-commercialize a PD-L1xVEGF drug that the German company had acquired from Biotheus. During a recent investor event, Pfizer’s newly minted Chief Oncology Officer, Jeff Legos, Ph.D., touted the New York pharma’s antibody-drug conjugates as potential combinable assets with SSGJ-707.“Part of this development plan will be to look at the inter-portfolio combination opportunities, particularly with some of our ADCs where we’ve been generating evidence that combinations with anti-PD-1 agents can deliver potentially practice-changing results,” Legos said.Summit previously formed a clinical collaboration with Pfizer. But that partnership is dead now with Pfizer’s 3SBio deal.Meanwhile, industry watchers are still awaiting detailed data or readouts from three ivonescimab phase 3 trials.The Chinese HARMONi-6 trial, which is evaluating ivonescimab against BeOne Medicines’ PD-1 inhibitor Tevimbra in their respective combinations with chemotherapy in first-line squamous non-small cell lung cancer, recently met its primary endpoint of progression-free survival.The Leerink team sees reduced near-term implications from this study for Summit because the trial is likely too early to show overall survival outcomes.A readout from the global HARMONi trial in EGFR-mutated NSCLC recently disappointed investors. While positive on progression-free survival, the study did not meet the overall survival goal at the time of the readout. Summit did not provide a breakdown of overall survival data in Asian and North American patients but said both groups showed a positive trend.As Leerink sees it, the most important ivonescimab readout in the near term is the China-only HARMONi-2 study. The high-profile Keytruda head-to-head study has repeatedly made headlines. There, ivonescimab monotherapy has decisively beaten Merck & Co.’s Keytruda in first-line PD-L1-positive NSCLC. The entire oncology field is waiting for its overall survival readout after a premature look at the data led to divided reviews. As Summit’s stock price fluctuates, the company’s board in April shifted the goalpost of the company’s executive compensation plan. Specifically, Summit has switched the remaining stock option awards issued under its 2020 stock incentive plan from performance-based to require only continued service with the firm.The new plan was laid out in the company's annual proxy (PDF) statements filed shortly after the unplanned HARMONi-2 overall survival readout had crashed Summit's stock price. To justify the decision, the board cited “consideration of the compensation program overall” and “the achievement of the market capitalization performance condition.”As a result of the modification, half of the remaining stock options vested in the second quarter, leading to an aggregate expense of $467 million. The remaining half will vest in three annual tranches beginning in October 2025, according to the firm’s proxy filing in April.

Phase 3License out/in

11 Aug 2025

·www.prnewswire.com

Akeso Announces First Patient Dosed in Phase III Trial of Ivonescimab as Consolidation Therapy for Limited-Stage SCLC After Definitive Radiotherapy

HONG KONG, Aug. 10, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its multicenter, randomized, double-blind Phase III study (AK112-311/HARMONi-9), evaluating ivonescimab, a first-in-class PD-1/VEGF bispecific antibody developed by Akeso, in small cell lung cancer (SCLC). This study is designed to assess the efficacy and safety of ivonescimab as consolidation therapy in patients with limited-stage small cell lung cancer (LS-SCLC) who have not experienced progression following standard concurrent chemoradiotherapy (cCRT). AK112-311/HARMONi-9 study is the eighth registrational Phase III clinical trial for ivonescimab in lung cancer (including three international multicenter studies). The initiation of this trial further expands ivonescimab's therapeutic coverage across key lung cancer indications and different lines of treatment. As the world's first PD-1/VEGF bispecific antibody, ivonescimab is driving significant transformation in the overall lung cancer treatment landscape and holds the potential to fundamentally improve global lung cancer therapies. Small cell lung cancer (SCLC) represents approximately 15% of all lung cancers and is known for its aggressive nature, early metastasis, and poor prognosis. Around 30% of patients are diagnosed at the limited stage (LS-SCLC), with over 80% being ineligible for surgical intervention. The current standard of care involves concurrent or sequential chemoradiotherapy (cCRT/sCRT), where most patients face recurrence or develop drug resistance. To date, only one PD-L1 therapy has been approved for consolidation treatment for LS-SCLC, highlighting the significant unmet clinical need of this difficult to treat cancer. In previous studies focused on extensive-stage SCLC (ES-SCLC), ivonescimab has demonstrated its ability to prolong progression-free survival (PFS), combining the synergistic benefits of PD-1/L1 inhibitors and anti-angiogenic agents. Ivonescimab is a cornerstone in Akeso's "IO 2.0" strategy, and Akeso has already initiated a series of Phase III and Phase II clinical trials investigating ivonescimab as a first-line treatment across multiple cancer indications. The initiation of a Phase III study of ivonescimab for LS-SCLC is another key step in extending Akeso's "IO 2.0" approach to earlier stages of lung cancer. Forward-Looking Statement of Akeso, Inc. This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law. About Akeso Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode, and has gradually developed into a globally competitive biopharmaceutical company focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 24 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available, and 2 new drugs with 2 new indications are under regulatory review for approval. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise. For more information, please visit and follow us on Linkedin. SOURCE Akeso, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 3Phase 2

100 Deals associated with Ivonescimab

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
PD-L1 positive Non-Small Cell Lung Cancer	China	Akeso-Sino Pharma Co., Ltd.	22 Apr 2025
EGFR positive Non-squamous non-small cell lung cancer	China	Akeso-Sino Pharma Co., Ltd.	21 May 2024

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Lung Non-Small Cell Squamous Carcinoma	NDA/BLA	China	Akeso Pharmaceuticals, Inc.	25 Jul 2025
Advanced Lung Non-Small Cell Squamous Carcinoma	NDA/BLA	China	Akeso-Sino Pharma Co., Ltd.	25 Jul 2025
Non-Small Cell Lung Cancer	Phase 3	China	Akeso Biopharma Co., Ltd.	30 Jun 2025
Advanced Lung Non-Small Cell Carcinoma	Phase 3	-	Akeso Biopharma Co., Ltd.	01 Jun 2025
Small Cell Lung Cancer	Phase 3	China	Akeso Biopharma Co., Ltd.	29 May 2025
Small cell lung cancer limited stage	Phase 3	China	Akeso Biopharma Co., Ltd.	29 May 2025
Metastatic Pancreatic Cancer	Phase 3	China	Akeso Biopharma Co., Ltd.	14 May 2025
Adenocarcinoma of large intestine	Phase 3	China	Akeso Biopharma Co., Ltd.	09 May 2025
Metastatic Colorectal Carcinoma	Phase 3	China	Akeso Biopharma Co., Ltd.	09 May 2025
PD-L1 negative Triple Negative Breast Cancer	Phase 3	China	Akeso Biopharma Co., Ltd.	07 Feb 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06396065 (HARMONi, NEWS 1 \| NEWS 2) Manual	Phase 3	Non-squamous non-small cell lung cancer Second line EGFR Mutation	-	ivonescimab +化疗	uiuldehvec(rylbunskar): 0.52 (95.0% CI, 0.41 - 0.66), P-Value = <0.00001 View more	Positive	30 May 2025
				化疗
NCT06375486 (ASCO2025)	Phase 2	Unresectable Hepatocellular Carcinoma First line HBV infection \| portal vein tumor thrombosis \| extrahepatic spread	27	Ivonescimab + HAIC	pealpkrhom(cjetglwtif) = sntmarqxpt emhcbsdlbd (kywrxxiyxc ) View more	Positive	30 May 2025
NCT05899608 (HARMONi-3, ASCO2025)	Phase 3	metastatic non-small cell lung cancer First line \| Maintenance	1,080	Ivonescimab plus chemotherapy	lxxsckaufb(hifyxnkmpp) = eeuvyfjyib nrwvwrifmi (kzgmrbcjmj ) View more	Positive	30 May 2025
				Pembrolizumab plus chemotherapy	lxxsckaufb(hifyxnkmpp) = skabrxspho nrwvwrifmi (kzgmrbcjmj ) View more
NCT05840016 (AK112-306 \| HARMONi-6, Company_Website) Manual	Phase 3	Squamous non-small cell lung cancer First line	532	ivonescimab + chemotherapy	ziqrepcvih(iorbcpiyqa) = in the intention-to-treat (ITT) population, ivonescimab plus chemotherapy decisively beat tislelizumab plus chemotherapy in terms of progression-free survival (PFS). saxkxakala (wkzgcebgkj ) Met View more	Superior	22 Apr 2025
				tislelizumab + chemotherapy
NEWS Manual	Phase 2	Resectable Lung Non-Small Cell Carcinoma Neoadjuvant	-	伊沃西单抗 20 mg/kg (队列1)	tjfyjmydob(ymghjnbftw) = syojmyicxj amnkeaclni (chuxjfpjpe ) View more	Positive	20 Jan 2025
				伊沃西单抗 20 mg/kg或30 mg/kg + 联合化疗 (队列2)	tjfyjmydob(ymghjnbftw) = eawbmdvpio amnkeaclni (chuxjfpjpe ) View more
NCT05184712 (HARMONi-A, ESMO_IO2024 \| NEWS) Manual	Phase 3	EGFR-mutated non-small Cell Lung Cancer EGFR Mutation	322	Ivonescimab (Ivo) + Pemetrexed/Carboplatin	wujxziiwih(rqhcesfpgi) = gelcpqocmq mibltgookm (fbjomvaaet ) View more	Positive	12 Dec 2024
				Placebo + Pemetrexed/Carboplatin	wujxziiwih(rqhcesfpgi) = zjvzkqlczr mibltgookm (fbjomvaaet ) View more
NCT05227664 (SABCS2024) Manual	Phase 2	Triple Negative Breast Cancer First line	30	Ivonescimab + Paclitaxel/Nab-paclitaxel	woypoirygt(ftpjtkgeen) = xungbjzcvx benbuchqqm (dfywmqzokt ) View more	Positive	26 Nov 2024
				Ivonescimab + Paclitaxel/Nab-paclitaxel (PD-L1 CPS ≥10)	woypoirygt(ftpjtkgeen) = vjuflymazx benbuchqqm (dfywmqzokt ) View more
NCT05227664 (ESMO2024) Manual	Phase 2	Triple Negative Breast Cancer First line HER2 Negative \| ER Negative \| PR Negative	30	Ivonescimab 20Paclitaxel + Pnab-paclitaxelg/m2	dctdowzopd(bsttxrurrw) = mxxoppzdsm ohdxyloijd (pdnyuatrfs ) View more	Positive	16 Sep 2024
				Ivonescimab 20Paclitaxel + Nnab-paclitaxel100 mg/m2	dctdowzopd(bsttxrurrw) = qkahigolrz ohdxyloijd (pdnyuatrfs ) View more
NCT05229497 (ESMO2024) Manual	Phase 2	Squamous Cell Carcinoma of Head and Neck First line PD-L1 Positive	30	Ivonescimab monotherapy	argdwxneiz(atyeuskdno) = pfvyiddeaj arthrhgdha (jibxwqaevc ) View more	Positive	14 Sep 2024
				Ivonescimab plus ligufalimab	argdwxneiz(atyeuskdno) = pjnfovulny arthrhgdha (jibxwqaevc ) View more
NCT05382442 (ESMO2024) Manual	Phase 2	Metastatic Colorectal Carcinoma First line KRAS \| BRAF \| MSS	40	FOLFOXIRI + Ivonescimab	njqipjnlsb(qmkqppjhyq) = fkierdsyfh mewbdbyypa (pppvqswmyi ) View more	Positive	14 Sep 2024
				FOLFOXIRI + Ivonescimab + Ligufalimab	njqipjnlsb(qmkqppjhyq) = bzaojmpdoq mewbdbyypa (pppvqswmyi ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis